SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

News > Suppliers

Read more breaking news

 

 

Horphag CEO: We’ve had our best ever three month period

By Stephen Daniells , 02-Apr-2012
Last updated on 02-Apr-2012 at 15:25 GMT2012-04-02T15:25:42Z

Cochrane Review has had
Cochrane Review has had "no impact" on business - Victor Ferrari

Sales of Pycnogenol, a potent antioxidant from the bark of the French maritime pine, continue to drive growth for Horphag Research, as the company’s CEO reveals double digit growth.

“We’re experiencing our best three months,” Horphag’s CEO Victor Ferrari told NutraIngredients-USA. “We posted double digit growth last year, and we’re set to post that again.”

The majority of the sales for the company have come in dietary supplements, with South America, Asia, and Japan showing particular growth, he added.

Pycnogenol - a combination of procyanidins, bioflavonoids and organic acids extracted from the bark of the maritime pine – is included in more than 700 dietary supplements, cosmetic products and functional foods and beverages worldwide.

Backed by science, challenged by Cochrane

The company’s ingredient has been the subject of scores of clinical studies suggesting benefits covering everything from cardiovascular, joint, cognitive and eye health to the relief of hay fever, PMS, tinnitus, hemorrhoidal pain and menopause symptoms.

Despite a scientific portfolio of almost 100 studies, the prestigious Cochrane organization recently made the ingredient the focus of a review, and concluded that “current evidence is insufficient to support Pycnogenol use for the treatment of any chronic disorder”.

The review included 15 clinical studies with a total of 791 participants related to the use of the pine bark extract in chronic disorders: asthma, attention deficit disorder, chronic venous insufficiency, diabetes, erectile dysfunction, hypertension and arthritis.

Despite the prestige of the Cochrane organization, the review’s conclusions have had “no impact” on business, said Ferrari.

Diverse science

Frank Schönlau, PhD, scientific director at Horphag, told NutraIngredients-USA that the conclusions were “predictable”.  

“The research on Pycnogenol is too diverse in terms of investigated health conditions and underlying pathologies. As an example, blood pressure improvements were shown in one study with normo-tensive menopausal women, another in metabolic syndrome patients, in another study Pycnogenol was taken in addition to prescription hypotensive medication, and yet another in people with kidney problems.

“The diversity of subject population and concomitant medications do not allow for carrying out meaningful meta‐analyses and hence the judgment had to result in the conclusion that further research is required to make conclusions.”

“How do you pool data for asthma, ADHD, osteoarthritis, and the other health conditions?” he asked.

While the company was not surprised by the conclusions, Ferrari and Schönlau took exception to the authors’ judgment on possible “study selective reporting bias”.

“This is scientifically unfounded and according to the publication was exclusively based on author’s arbitrary impression followed by consensus,” they said.

The company has a general rule of signing ‘no conflict of interest’ declarations between Horphag Research and cooperating research institutions, they said.

“Horphag Research continues its commitment to research and will continue to be one of the leading companies in the field of evidence-based nutraceuticals,” they added.

Source: The Cochrane Library
Published Online 15 February 2012, doi: 10.1002/14651858.CD008294.pub3
“Pycnogenol for the treatment of chronic disorders”
Authors: A. Schoonees, J. Visser, A. Musekiwa, J. Volmink

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars